Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing

Front Immunol. 2024 Feb 28:15:1389603. doi: 10.3389/fimmu.2024.1389603. eCollection 2024.

Authors

Michel Demeule¹, Jean-Christophe Currie¹, Cyndia Charfi¹, Alain Zgheib², Isabelle Cousineau², Véronique Lullier², Richard Béliveau², Christian Marsolais¹, Borhane Annabi²

Affiliations

¹ Theratechnologies Inc., Montréal, QC, Canada.
² Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1355945.].

Keywords: PD-L1; STING; checkpoint inhibitor; docetaxel; immune tumor microenvironment; peptide-drug conjugate; sortilin.

Copyright © 2024 Demeule, Currie, Charfi, Zgheib, Cousineau, Lullier, Béliveau, Marsolais and Annabi.

Publication types

Published Erratum